info@seagull-health.com
SeagullHealth
search
Capmatinib(Tabrecta)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Tabrecta(Capmatinib) Instructions:Uses,Dosage, Side Effects
TABRECTA, with the generic name Capmatinib, is a targeted kinase inhibitor therapy. Its active pharmaceutical ingredient is capmatinib, formulated as film-coated tablets available in 150 mg and 200 mg strengths. The drug is specifically designed to target and inhibit the MET kinase, including the mutant variant caused by MET exon 14 skipping. This mutation leads to dysregulated MET signaling and drives cancer growth. TABRECTA is manufactured and distributed by Novartis Pharmaceuticals Corporation for oral administration in eligible adult patients.
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.
The recommended dosage is 400 mg taken orally twice daily, with or without food.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
